John E. Godwin

机构：Providence Portland Medical Center · ORCID：0000-0003-3876-2505

发表论文 187 篇 · 总被引 6579 次 · h-index 35

代表论文

• Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia (2020 · Blood · 被引 332)
• Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study (2022 · The Lancet Oncology · 被引 242)
• TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML (2020 · Blood Advances · 被引 156)
• Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma (2020 · American Journal of Hematology · 被引 99)
• AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report (2020 · Biomarker Research · 被引 36)
• Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study (2019 · Blood · 被引 32)